Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial - Eijkelkamp, W B; Zhang, Z; Remuzzi, G (J Am Soc Nephrol, 2007)
et al.